Equisul-SDT Oral Suspension is a broad-spectrum antimicrobial from the potentiated sulfonamide class of chemotherapeutic agents. These two drugs block different sequential steps in the biosynthesis of nucleic acids. Sulfadiazine inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by reversibly inhibiting dihydrofolate reductase. The effect of the dual action is to reduce the minimum inhibitory concentration of each agent (synergism) and to convert a bacteriostatic action to a bactericidal action. Sulfadiazine is the non-proprietary name for 4-amino-N-2-pyrimidi-nylbenzenesulfonamide. Trimethoprim is the non-proprietary name for 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine.

FEATURES / BENEFITS

EQUISUL-SDT is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subsp. zooepidemicus.

EQUISUL-SDT is proven effective in horses for the treatment of lower respiratory tract infections caused by susceptible strains of Streptococcus equi subsp. zooepidemicus in controlled field trials.

EQUISUL-SDT safety was demonstrated in a controlled study in horses at 1X, 3X and 5X the recommended dose for 30 days.

Easy-to-use, apple-f lavored liquid formulation

Significantly higher bioavailability on a mg-to-mg basis compared to an existing approved paste product, based on a pharmacokinetic crossover study.

Low incidence of side effects in our controlled safety studies.

SPECIFICATIONS

Safety was demonstrated in a controlled study in horses at 1X, 3X and 5X the recommended dose for 30 days

Do not use in horses intended for human consumption.

Store upright at 59°– 86° F (15°– 30° C). Brief periods up to 104° F (40° C) are permitted. Protect from freezing.

Discard 60 days after removing bottle seal.

Significantly higher bioavailability on a mg-to-mg basis compared to an approved paste product, based on a pharmacokinetic crossover study

INSTRUCTIONS

Shake well before use. Remove cap. Peel off white foil backed bottle seal and replace cap. Peel off outer cap seal exposing (hole) opening. Push an oral tip syringe into the cap opening. Invert and draw out appropriate volume of EQUISUL-SDT solution. (Note: Do not remove syringe while the bottle is inverted as possible spillage may result.) Detach syringe and administer orally at the dosage of 24 mg combined active ingredients per kilogram body weight (10.9 mg/lb) twice daily for 10 days. EQUISUL-SDT can be administered by volume at 2.7 mL per 45.4 kg (2.7 mL/100 lb) body weight